TransCode Therapeutics【RNAZ】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.5693

買値

0.41

売値

1.00

出来高

830,172

0.5456 日の範囲 0.6431

0.216 52 週間の範囲 21.20

時価総額

9.829M

前日終値

0.613

始値

0.6431

時刻

0.58

最終取引時間

財務取引量

US$ 497,735

VWAP

0.599557

平均取引量 (3 か月)

1,998,977

発行済株式数

17,265,658

配当利回り

PER

-0.54

1 株当たり利益 (EPS)

-1.07

歳入

純利益

-18.55M

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regre... TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.transcodetherapeutics.com

本社

Wilmington, Delaware, USA

設立

TransCode Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker RNAZ. The last closing price for TransCode Therapeutics was US$0.61. Over the last year, TransCode Therapeutics shares have traded in a share price range of US$ 0.216 to US$ 21.20.

TransCode Therapeutics currently has 17,265,658 shares in issue. The market capitalisation of TransCode Therapeutics is US$10.58 million. TransCode Therapeutics has a price to earnings ratio (PE ratio) of -0.54.

Form 8-K - Current report

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Two patients dosed; several additional patients screened for enrollmentTrial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancerTTX-MC138 is an antisense...

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer

BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, in...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0367	-6.05610561056	0.606	0.6985	0.41	1926841	0.58632923	CS
4	0.3063	116.463878327	0.263	0.73	0.2353	2674304	0.48357796	CS
12	-0.2746	-32.5394004029	0.8439	0.98	0.216	1998977	0.37984091	CS
26	-0.086	-13.1237601099	0.6553	2.01	0.216	1568027	0.6525117	CS
52	-19.4307	-97.1535	20	21.2	0.216	2252772	8.14802827	CS
156	-2295.4307	-99.9752047038	2296	2768	0.216	1457494	231.38344384	CS
260	-4799.4307	-99.9881395833	4800	5600	0.216	1709644	872.47163045	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
CHSNChanson International Holding	US$ 11.22 (269.08%)	14.76M
PEVPhoenix Motor Inc	US$ 1.0607 (205.24%)	228.42M
ENTOEntero Therapeutics Inc	US$ 0.60 (72.20%)	10.42M
BENFBeneficient	US$ 1.8914 (58.94%)	108.31M
FORDForward Industries Inc	US$ 5.3254 (52.15%)	18.45M
ADDColor Star Technology Company Ltd	US$ 0.2701 (-39.98%)	14.35M
DUOFangDD Network Group Ltd	US$ 2.53 (-32.89%)	27.74M
ICCTiCoreConnect Inc	US$ 0.4102 (-31.50%)	1.65M
ZENAZenaTech Inc	US$ 3.91 (-29.55%)	212.12k
SPAISafe Pro Group Inc	US$ 1.93 (-25.77%)	238.67k
NVDANVIDIA Corporation	US$ 124.92 (1.68%)	234.27M
PEVPhoenix Motor Inc	US$ 1.0607 (205.24%)	223.68M
SQQQProShares UltraPro Short QQQ	US$ 7.43 (-3.63%)	175.65M
NCNCnoco noco Inc	US$ 0.144 (8.60%)	141.12M
BENFBeneficient	US$ 1.8914 (58.94%)	101M